help button home button Am J Pathol Epitomics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stoeltzing, O.
Right arrow Articles by Ellis, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stoeltzing, O.
Right arrow Articles by Ellis, L. M.
(American Journal of Pathology. 2003;163:1001-1011.)
© 2003 American Society for Investigative Pathology

Regulation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor, and Angiogenesis by an Insulin-Like Growth Factor-I Receptor Autocrine Loop in Human Pancreatic Cancer

Oliver Stoeltzing*, Wenbiao Liu*, Niels Reinmuth*, Fan Fan*, Alexander A. Parikh{dagger}, Corazon D. Bucana*, Douglas B. Evans{dagger}, Gregg L. Semenza{ddagger} and Lee M. Ellis*{dagger}

From the Departments of Cancer Biology*and Surgical Oncology,{dagger}The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and the Departments of Pediatrics and Medicine and McKusick-Nathans Institute of Genetic Medicine,{ddagger}The Johns Hopkins University School of Medicine, Baltimore, Maryland

Activation of the insulin-like growth factor-I receptor (IGF-IR) was recently shown to modulate angiogenesis by up-regulating the expression of vascular endothelial growth factor (VEGF). We hypothesized that inhibiting IGF-IR function would inhibit angiogenesis and growth of pancreatic cancer in vivo and sought to identify major signaling pathways regulated by IGF-IR in pancreatic cancer cells. Human pancreatic cancer cells (L3.6pl) were stably transfected with a dominant-negative form of IGF-IR (IGF-IR DN) or an empty vector (pcDNA). In vitro, IGF-IR DN cells exhibited a decrease in both constitutive and inducible phosphorylation of IGF-IR and Erk1/2. Constitutive expression of nuclear hypoxia-inducible factor-1{alpha} and secreted VEGF (P < 0.01) protein levels also were significantly lower in IGF-IR DN cells than in pcDNA cells. In vivo, IGF-IR inhibition led to decreases in pancreatic tumor volume and weight, vessel density, and tumor cell proliferation (P < 0.01 for all) and increases in tumor cell apoptosis (P < 0.02). Our results suggest that autocrine activation of the IGF-IR system significantly affects VEGF expression and angiogenesis in human pancreatic cancer. Thus, IGF-IR may be a valid target in the treatment of pancreatic cancer.





This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
H. Suzuki, Y. Li, X. Dong, M. M. Hassan, J. L. Abbruzzese, and D. Li
Effect of Insulin-Like Growth Factor Gene Polymorphisms Alone or In Interaction with Diabetes on the Risk of Pancreatic Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3467 - 3473.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. A. Lang, P. Schachtschneider, C. Moser, A. Mori, C. Hackl, A. Gaumann, D. Batt, H. J. Schlitt, E. K. Geissler, and O. Stoeltzing
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
Mol. Cancer Ther., November 1, 2008; 7(11): 3509 - 3518.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
W. Liu, D. A. Bloom, W. G. Cance, E. V. Kurenova, V. M. Golubovskaya, and S. N. Hochwald
FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells
Carcinogenesis, June 1, 2008; 29(6): 1096 - 1107.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. Moser, S. A. Lang, S. Kainz, A. Gaumann, S. Fichtner-Feigl, G. E. Koehl, H. J. Schlitt, E. K. Geissler, and O. Stoeltzing
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo
Mol. Cancer Ther., November 1, 2007; 6(11): 2868 - 2878.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. A. Lang, C. Moser, A. Gaumann, D. Klein, G. Glockzin, F. C. Popp, M. H. Dahlke, P. Piso, H. J. Schlitt, E. K. Geissler, et al.
Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal-Transducer and Activator of Transcription 3/Hypoxia-Inducible Factor-1{alpha} Autocrine Loop, and Reduces Orthotopic Tumor Growth
Clin. Cancer Res., November 1, 2007; 13(21): 6459 - 6468.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
T. W. Bauer, F. Fan, W. Liu, E. R. Camp, A. Yang, R. J. Somcio, C. D. Bucana, R. Singh, and L. M. Ellis
Targeting of Insulin-like Growth Factor-I Receptor with a Monoclonal Antibody Inhibits Growth of Hepatic Metastases from Human Colon Carcinoma in Mice
Ann. Surg. Oncol., October 1, 2007; 14(10): 2838 - 2846.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. M. Wolpin, D. S. Michaud, E. L. Giovannucci, E. S. Schernhammer, M. J. Stampfer, J. E. Manson, B. B. Cochrane, T. E. Rohan, J. Ma, M. N. Pollak, et al.
Circulating Insulin-Like Growth Factor Binding Protein-1 and the Risk of Pancreatic Cancer
Cancer Res., August 15, 2007; 67(16): 7923 - 7928.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
S Llewellyn, R Fitzpatrick, D A Kenny, J J Murphy, R J Scaramuzzi, and D C Wathes
Effect of negative energy balance on the insulin-like growth factor system in pre-recruitment ovarian follicles of post partum dairy cows
Reproduction, March 1, 2007; 133(3): 627 - 639.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. A. Lang, D. Klein, C. Moser, A. Gaumann, G. Glockzin, M. H. Dahlke, W. Dietmaier, U. Bolder, H. J. Schlitt, E. K. Geissler, et al.
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo
Mol. Cancer Ther., March 1, 2007; 6(3): 1123 - 1132.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. C. Manara, L. Landuzzi, P. Nanni, G. Nicoletti, D. Zambelli, P. L. Lollini, C. Nanni, F. Hofmann, C. Garcia-Echeverria, P. Picci, et al.
Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma
Clin. Cancer Res., February 15, 2007; 13(4): 1322 - 1330.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
F. Wang, S. S. Li, R. Segersvard, L. Strommer, K.-G. Sundqvist, J. Holgersson, and J. Permert
Hypoxia Inducible Factor-1 Mediates Effects of Insulin on Pancreatic Cancer Cells and Disturbs Host Energy Homeostasis
Am. J. Pathol., February 1, 2007; 170(2): 469 - 477.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S.-H. Oh, O.-H. Lee, C. P. Schroeder, Y. W. Oh, S. Ke, H.-J. Cha, R.-W. Park, A. Onn, R. S. Herbst, C. Li, et al.
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
Mol. Cancer Ther., November 1, 2006; 5(11): 2685 - 2695.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. W. Bauer, R. J. Somcio, F. Fan, W. Liu, M. Johnson, D. P. Lesslie, D. B. Evans, G. E. Gallick, and L. M. Ellis
Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells.
Mol. Cancer Ther., July 1, 2006; 5(7): 1676 - 1682.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty and K. I. Block
Toward a Core Nutraceutical Program for Cancer Management
Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171.
[Abstract] [PDF]


Home page
Genes Dev.Home page
A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho
Genetics and biology of pancreatic ductal adenocarcinoma.
Genes & Dev., May 15, 2006; 20(10): 1218 - 1249.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. M. du Manoir, G. Francia, S. Man, M. Mossoba, J. A. Medin, A. Viloria-Petit, D. J. Hicklin, U. Emmenegger, and R. S. Kerbel
Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts
Clin. Cancer Res., February 1, 2006; 12(3): 904 - 916.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
M Munoz-Gutierrez, P A Findlay, C L Adam, G Wax, B K Campbell, N R Kendall, M Khalid, M Forsberg, and R J Scaramuzzi
The ovarian expression of mRNAs for aromatase, IGF-I receptor, IGF-binding protein-2, -4 and -5, leptin and leptin receptor in cycling ewes after three days of leptin infusion
Reproduction, December 1, 2005; 130(6): 869 - 881.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Q. Zhang, X. Tang, Q. Y. Lu, Z. F. Zhang, J. Brown, and A. D. Le
Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1{alpha} and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells
Mol. Cancer Ther., October 1, 2005; 4(10): 1465 - 1474.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. W. Bauer, W. Liu, F. Fan, E. R. Camp, A. Yang, R. J. Somcio, C. D. Bucana, J. Callahan, G. C. Parry, D. B. Evans, et al.
Targeting of Urokinase Plasminogen Activator Receptor in Human Pancreatic Carcinoma Cells Inhibits c-Met- and Insulin-like Growth Factor-I Receptor-Mediated Migration and Invasion and Orthotopic Tumor Growth in Mice
Cancer Res., September 1, 2005; 65(17): 7775 - 7781.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
R. Korn, S. Rohrig, S. Schulze-Kremer, and U. Brinkmann
Common denominator procedure: a novel approach to gene-expression data mining for identification of phenotype-specific genes
Bioinformatics, June 1, 2005; 21(11): 2766 - 2772.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Stearns, J. Tran, M. K. Francis, H. Zhang, and C. Sell
Activated Ras Enhances Insulin-Like Growth Factor I Induction of Vascular Endothelial Growth Factor in Prostate Epithelial Cells
Cancer Res., March 15, 2005; 65(6): 2085 - 2088.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. T. Henke, B. R. Haddad, S. E. Kim, J. D. Rone, A. Mani, J. M. Jessup, A. Wellstein, A. Maitra, and A. T. Riegel
Overexpression of the Nuclear Receptor Coactivator AIB1 (SRC-3) during Progression of Pancreatic Adenocarcinoma
Clin. Cancer Res., September 15, 2004; 10(18): 6134 - 6142.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Z. Cao, J. Fang, C. Xia, X. Shi, and B.-H. Jiang
trans-3,4,5'-Trihydroxystibene Inhibits Hypoxia-Inducible Factor 1{alpha} and Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells
Clin. Cancer Res., August 1, 2004; 10(15): 5253 - 5263.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
K. R. Laderoute, J. M. Calaoagan, M. Knapp, and R. S. Johnson
Glucose Utilization Is Essential for Hypoxia-Inducible Factor 1{alpha}-Dependent Phosphorylation of c-Jun
Mol. Cell. Biol., May 15, 2004; 24(10): 4128 - 4137.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society for Investigative Pathology.